All articles by Miranda Mclaren

Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools

While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other…
Annex 1 sterilisation: Why pharma packaging strategy is changing

The revised EU GMP Annex 1 has ushered in a new phase for sterile manufacturing. Published in 2022, with most…
Early Biomarkers as Predictors of Nephrology Trial Trajectory

Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
The evolution of the ADC market – and what it means for commercial packaging

The ADC market The first antibody drug conjugate (ADC) was approved in 2000 by pairing a cytotoxic chemotherapy agent with…
Complementing DepMap: Expanding the toolkit for oncology target discovery and de-risking

With cancer responsible for one in six deaths around the world, precision medicines based on the root cause of the…

Designing vial systems to meet the demands of complex biologics

Large molecule medicines are transforming treatment paradigms for many chronic and debilitating diseases, targeting previously “undruggable” pathways and marking a…
The future role of automation and AI in environmental monitoring

In pharmaceutical manufacturing, robust environmental monitoring is crucial for maintaining product quality and regulatory compliance. Historically, these practices have been…
Q&A: How 3PLs are navigating the latest pharma trends

Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
The Ovarian Cancer Opportunity: Overcoming Complexity in Global Studies

Each year in the US, more than 21,000 women will receive a new diagnosis of ovarian cancer according to the…
Trends in Renal Research: Nephrology’s Shift to Focus and Precision

Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained…

Sections